("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive results from the company's Phase 1 multiple ascending dose (MAD) clinical trial of an oral tablet formulation of VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, in development for the potential treatment of metabolic disorders such as obesity
BPC-157 at a dose of 10 g/kg or 10 g/kg was given immediately after lidocaine administration, along with lidocaine, while the control group received saline
Other GLP-1 provider reviews worth reading If you are researching tirzepatide providers, comparing multiple options is the smartest approach
Compounded peptides remain cash-pay almost universally but if youre considering brand-name semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound), expect insurer-specific PA timelines that vary materially
Understanding whether you carry variants associated with GLP-1R sensitivity, GIPR signaling, or FTO-driven weight regulation may help provide context for your provider conversation about which GLP-1 option and dosing strategy align with your genetic profile
